Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...

Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Q32 Bio (QTTB – Research Report) today and set a price target of $20.00.

Short interest in Q32 Bio Inc (NASDAQ:QTTB) increased during the last reporting period, rising from 678.64K to 686.07K. This put -% of the company's publicly available shares short. Short interest ...

Key Insights Significant control over Q32 Bio by private equity firms implies that the general public has more power ...

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today encouraging initial clinical data from the first dose cohort in the pheEDIT Phase 1, ...

Equities researchers at BMO Capital Markets began coverage on shares of Q32 Bio (NASDAQ:QTTB – Get Free Report) in a research note issued on Friday, Marketbeat Ratings reports. The brokerage set an ...

Fintel reports that on December 6, 2024, BMO Capital initiated coverage of Q32 Bio (NasdaqGM:QTTB) with a Outperform recommendation. As of December 3, 2024, the average one-year price target for ...